Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Dragon Pharma announces sufficient votes based on receipt of preliminary proxies to approve Merger

Dragon Pharmaceutical Inc. announced that based on the receipt of preliminary proxies, the Company believes that it has sufficient votes to approve the Agreement and Plan of Merger by and among Dragon, Chief Respect Limited, Datong Investment Inc., a subsidiary of Chief Respect Limited, and Mr. Yanlin Han.

8 Jul 2010

PolyMedix receives NIH grant to develop defensin-mimetic antimicrobial compounds for malaria

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a grant from the National Institute of Health (NIH) to support the development of defensin-mimetic antimicrobial compounds for the treatment of malaria.

7 Jul 2010

Communication between bacterial species promotes resistance to antibiotics: Study

Ear infections caused by more than one species of bacteria could be more persistent and antibiotic-resistant because one pathogen may be communicating with the other, encouraging it to bolster its defenses. Interrupting or removing that communication could be key to curing these infections. Researchers from Wake Forest University Baptist Medical Center publish their findings today in mBio-, the online open-access journal of the American Society for Microbiology.

7 Jul 2010

EUSA grants Ohara Japanese rights to Erwinase oncology therapy

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has granted the Japanese development and commercialization rights to its oncology therapy Erwinase(R) to Ohara Pharmaceutical Company Limited. The agreement represents the first product partnership EUSA has established in Japan.

6 Jul 2010

MabCent finds extraordinary life forms in the Arctic

During its short existence the Centre on Marine Bioactives and Drug Discovery (MabCent) in Tromsø has analysed some 70,000 fractions of Arctic marine organisms. Patents on two molecules have been applied for and applications for another 20 will soon follow.

3 Jul 2010

Karolinska researchers recommend new routine for protection against infection during PEG

Researchers at Karolinska Institutet recommends a new routine for protection against infection when percutaneous endoscopic gastrostomy (PEG), a tube for feeding directly through the abdominal wall, is surgically inserted in the stomach. The new routine is both simpler and cheaper than the one used today. The method, presented in the British Medical Journal, has been clinically tested on over 200 patients at the Karolinska University Hospital in Solna, Stockholm County, Sweden.

2 Jul 2010

Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that a second large, Phase III, international study showed that the combination of Avastin® (bevacizumab) and chemotherapy, followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening (progression-free survival or PFS, the primary endpoint), compared to chemotherapy alone.

2 Jul 2010

Patients receiving TMP-SMX antibiotics are more likely to develop hyperkalemia: Study

Older adults taking the antibiotic combination trimethoprim-sulfamethoxazole (TMP-SMX)—widely prescribed for urinary tract infections—are at increased risk of elevated potassium levels, called hyperkalemia, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

2 Jul 2010

Advanced Life Sciences prices securities offering

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has established the pricing terms of its proposed offering of units.

1 Jul 2010

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment of the first patient in a Phase 2 study with CXA-201. This multicenter, double-blind, randomized, study will compare the safety and efficacy of intravenous CXA-201 with an active comparator in patients with complicated intra-abdominal Infections (cIAI). This international study is expected to enroll 120 patients.

1 Jul 2010

Antibacterial ingredient in honey identified

Sweet news for those looking for new antibiotics: A new research published in the July 2010 print edition of the FASEB Journal explains for the first time how honey kills bacteria. Specifically, the research shows that bees make a protein that they add to the honey, called defensin-1, which could one day be used to treat burns and skin infections and to develop new drugs that could combat antibiotic-resistant infections.

30 Jun 2010

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives.

30 Jun 2010

Erye's new facility passes SFDA inspection for manufacture of penicillin, cephalosporin powder

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced on June 15, 2010 that its 51% owned Suzhou Erye pharmaceutical subsidiary passed the government inspection by the State Food and Drug Administration ("SFDA") in China to manufacture penicillin and cephalosporin powder for injection at its new manufacturing facility.

30 Jun 2010

'Beeglue' may help deliver new treatments for fatal infections

Bees could have a key role to play in urgently-needed new treatments to fight the virulent MRSA bug, according to research led at the University of Strathclyde in Glasgow, Scotland.

29 Jun 2010

Overview of scientific research on medical technology to combat anthrax threat

The 2001 anthrax attacks in the United States are fostering development of a new generation of vaccines, antibiotics, and other medications to protect people against the potentially deadly bacteria in any future bioterrorist incident. That's the conclusion of a sweeping overview of scientific research on medical technology to combat the anthrax threat. It appears in ACS' bi-weekly Journal of Medicinal Chemistry.

25 Jun 2010

Specific virus can interact with mutation in host's genes to trigger diseases: Scientists

Scientists have shown that a specific virus can interact with a mutation in the host's genes to trigger disease. The observation may help explain why many people with disease risk genes do not actually develop disease.

25 Jun 2010

Surgical care improvement measures associated with lower probability of postoperative infection: JAMA

An analysis of data on adherence to surgical care improvement measures finds that when analyzed as a composite infection-prevention score, the improvement measures were associated with a lower probability of postoperative infection. However, adherence to individual measures - the format of publicly reported performance data - was not associated with a significantly lower risk of infection, according to a study in the June 23/30 issue of JAMA.

25 Jun 2010

Study examines relationship between SCIP measures and postoperative infection

A study by investigators at Case Western Reserve University School of Medicine published in this week's issue of JAMA found that public hospital comparison data reported by the U.S. Department of Health and Human Services does not accurately correlate with a patient's risk for surgical postoperative infection.

24 Jun 2010

Aradigm announces $5 million private placement

Aradigm Corporation today announced that it has entered into a definitive agreement for the sale of common stock and warrants to three existing shareholders and one new investor in a private placement for aggregate gross proceeds of approximately $5 million. The closing of the private placement is subject to the satisfaction of customary closing conditions.

21 Jun 2010

ViroPharma provides update on recent progress in Cinryze manufacturing expansion activities

ViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing line and increasing the amount of drug supply available to patients suffering from hereditary angioedema, or HAE.

21 Jun 2010

Antibiotic News and Research

Further Reading

Dragon Pharma announces sufficient votes based on receipt of preliminary proxies to approve Merger

PolyMedix receives NIH grant to develop defensin-mimetic antimicrobial compounds for malaria

Communication between bacterial species promotes resistance to antibiotics: Study

EUSA grants Ohara Japanese rights to Erwinase oncology therapy

MabCent finds extraordinary life forms in the Arctic

Karolinska researchers recommend new routine for protection against infection during PEG

Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint

Patients receiving TMP-SMX antibiotics are more likely to develop hyperkalemia: Study

Advanced Life Sciences prices securities offering

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Antibacterial ingredient in honey identified

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Erye's new facility passes SFDA inspection for manufacture of penicillin, cephalosporin powder

'Beeglue' may help deliver new treatments for fatal infections

Overview of scientific research on medical technology to combat anthrax threat

Specific virus can interact with mutation in host's genes to trigger diseases: Scientists

Surgical care improvement measures associated with lower probability of postoperative infection: JAMA

Study examines relationship between SCIP measures and postoperative infection

Aradigm announces $5 million private placement

ViroPharma provides update on recent progress in Cinryze manufacturing expansion activities

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News